There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

Earlier in October, Pfizer Inc (NYSE ... On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher ...

Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer ...

the mRNA vaccines from Pfizer and Moderna — aren’t effective. Pfizer’s and Moderna’s vaccines were the first to use mRNA ...

Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Pfizer-BioNTech: The Pfizer-BioNTech vaccine ... performing almost as well as the mRNA vaccines in their early trials. The FDA authorized an updated COVID vaccine from Novavax at the end of ...